Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity
Misfolding of transthyretin can cause amyloid aggregation disorders that can be treated by stabilizing the tetrameric form with tafamidis. Here the authors show that tolcapone, a drug already FDA-approved for Parkinson disease, has strong transthyretin stabilizing function and might be a superior th...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | article |
| Language: | EN |
| Published: |
Nature Portfolio
2016
|
| Subjects: | |
| Online Access: | https://doaj.org/article/837ff0b26f1b42a594f1b539d90bcb7c |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|